Balloon Mitral Valvuloplasty (BMV) in Pregnancy: A Four-Year Experience at Shahid Gangalal National Heart Centre (SGNHC), Nepal

*Department of Cardiology Shahid Gangalal National Heart Centre, Bansbari

INTRODUCTION
Mitral stenosis (MS) primarily affects young women at reproductive age. Thus, pregnancy in MS patients is a common clinical problem in countries with high rheumatic disease prevalence like ours. MS contributes to significant morbidity in pregnancy. Pregnancy is associated with a 40-50% increase in cardiac output and a decrease in systemic vascular resistance but, in the presence of severe mitral stenosis, these changes cannot occur. Untreated, the haemodynamic effects of mitral stenosis, together with the risk of thromboembolism, can lead to significant maternal and fetal morbidity and mortality. For several decades surgical commissurotomy was being performed during pregnancy in patients with severe MS. However, BMV has been established as an effective method for treating MS in pregnancy with results comparable to surgical commissurotomy. Two BMV techniques have been extensively used: the inoue balloon technique and the transseptal over-the-wire balloon techniques. Studies to date have shown equal efficacy of the two BMV methods in terms of valve enlargement although the inoue approach is simpler, faster, and yielded similar benefits and is also associated with a lower risk of creating severe mitral regurgitation. However, the efficacy and safety of BMV in our subset is not known. We designed this study to evaluated the safety of BMV for the treatment of MS in pregnant women.

METHODS
Patients: Eight hundred and sixty one patient underwent BMV in Shahid Gangalal National heart centre (SGNHC) in past four years (from January 2003 to December 2007), out of whom 413 (47.97%) were male and 448 (52.03%) were female. Among them 22 were pregnant women with severe mitral stenosis at SGNHC from January 2003 to December 2007 were done. Mean fulroscopy time was 7.5±4.8 min. post-BMV, the mean left atrial pressure dropped from 28.1±4.3 mmHg to 15.3±6.4 mmHg. Mitral valve area as assessed by echocardiography increased from 0.76±0.21 cm² to 1.8±0.26 cm², all the patients showed symptomatic improvement. Six patients had an increase in MR by 2 grades. Twenty patients had a normal delivery while 2 underwent a caesarean section. There was no maternal morbidity or mortality in the peripartum period. On follow up for 26±15 months, all babies maintained normal growth and development without any thyroid disease or malignancy. During pregnancy BMV is feasible, safe and effective. Maternal and fetal outcomes are excellent. Growth and milestone of development are not affected.

Abstract
Balloon Mitral Valvuloplasty (BMV) has been performed safely during pregnancy with good results. This study was intended to see the efficacy and safety of BMV in this subset. Retrospective analysis of 22 pregnant women among a total of 861 patients who had undergone BMV for severe mitral stenosis at SGNHC from January 2003 to December 2007 were done. Mean fulroscopy time was 7.5±4.8 min. post-BMV, the mean left atrial pressure dropped from 28.1±4.3 mmHg to 15.3±6.4 mmHg. Mitral valve area as assessed by echocardiography increased from 0.76±0.21 cm² to 1.8±0.26 cm², all the patients showed symptomatic improvement. Six patients had an increase in MR by 2 grades. Twenty patients had a normal delivery while 2 underwent a caesarean section. There was no maternal morbidity or mortality in the peripartum period. On follow up for 26±15 months, all babies maintained normal growth and development without any thyroid disease or malignancy. During pregnancy BMV is feasible, safe and effective. Maternal and fetal outcomes are excellent. Growth and milestone of development are not affected.

Keywords: Balloon Mitral valvuloplasty, Pregnancy, Mitral Stenosis
similar to that used in Inoue-balloon BMV and was based on
body height.

Patients' clinical characteristics are shown in table 1.

<table>
<thead>
<tr>
<th>Table 1. Clinical characteristics</th>
<th>n=22</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>23.6±4.2</td>
</tr>
<tr>
<td>Gestation (weeks)</td>
<td>24.2±4.6</td>
</tr>
<tr>
<td>Mitral valve area (cm²)</td>
<td>0.76±0.21</td>
</tr>
<tr>
<td>Symptom class (NYHA)</td>
<td></td>
</tr>
<tr>
<td>Class I &amp; II</td>
<td>16</td>
</tr>
<tr>
<td>Class III</td>
<td>6</td>
</tr>
<tr>
<td>PAH</td>
<td>7 (44%)</td>
</tr>
<tr>
<td>Mild</td>
<td>12</td>
</tr>
<tr>
<td>Moderate to severe</td>
<td>10</td>
</tr>
<tr>
<td>LA Pressure (mmHg)</td>
<td>28.12±4.3</td>
</tr>
<tr>
<td>MR Nil/Grade I/II</td>
<td>13</td>
</tr>
<tr>
<td>Grade II/III</td>
<td>7</td>
</tr>
<tr>
<td>Grade III</td>
<td>2</td>
</tr>
</tbody>
</table>


RESULTS

The procedure was successful in all with no maternal mortality. Mean fluoroscopy time was 7.5±4.8 min. post-BMV, the mean left atrial pressure dropped from 28.12±4.3 mmHg to 15.32±6.4 mmHg. No patients was left with residual MS (MVA<1.5 cm²). Mitral valve area as assessed by echocardiography increased from 0.76±0.21 cm² to 1.8±0.26 cm². all the patients had symptomatic improvement. Six patients had an increase in mitral regurgitation (MR) by 2 grades. One patient had a mild tear of the anterior mitral leaflet, others had excessive commissural MR. none of the 6 patients required mitral valve replacement. There was a significant reduction in the pulmonary artery pressure after BMV. Twenty patients had a normal delivery while 2 underwent a caesarean section. There was no maternal morbidity or mortality such as maternal death, abortion, or intrauterine growth retardation in the peripartum period. On follow up for 26±15 months, all babies maintained normal growth and development without any thyroid disease or malignancy.

DISCUSSION

MS contributes to significant morbidity in pregnancy. Pregnancy is associated with a 40-50% increase in cardiac output and a decrease in systemic vascular resistance but, in the presence of severe mitral stenosis, these changes cannot occur. Untreated, the haemodynamic effects of mitral stenosis, together with the risk of thromboembolism, can lead to significant maternal and fetal morbidity and mortality. Large series of studies have proved the efficacy and safety of BMV in pregnant women with MS. As reported in other studies, in our series BMV produced impressive hemodynamic improvement including a decrease in left atrial and pulmonary artery pressure, and an increase in mitral valve area. Most of our patients had an ideal anatomy of mitral valve for BMV.

Very few complications have been reported with balloon mitral commissurotomy during pregnancy. Mitral regurgitation was increased by grade 2 in six patients in our series but none required to undergo mitral valve replacement. In one report, one patient had a spontaneous abortion. There were no maternal deaths in our series, in contrast, mortality from surgical closed mitral commissurotomy was reported to be as high as 3% and that from open commissurotomy reached 5%.

Fluoroscopic radiation exposure carries a potential risk to the unborn child. However, the risk is greatly diminished by appropriate and complete abdominal lead shielding, a short radiation exposure time, avoidance of left ventricular angiography, and performance of the procedure after the 14th week of gestation, when organogenesis has already been achieved. We, moreover, used Inoue balloon technique which seems to shorten the fluoroscopy time compared to the double balloon technique. In our study no baby had abnormalities related to radiation. Uneventful full term delivery was obtained in all patients, vaginally in 20; caesarean section was required in only two patients for obstetric reasons. There was no fetal death or preterm delivery. On follow up for 26±15 months, all babies maintained normal growth and development with no relative growth retardation. As yet, however, the long term outcome in these children remains unknown, since the future late appearance of radiation side effects cannot be excluded, though it must be very unlikely. Griem et al, in a 20 year follow up study of 1000 women irradiated for radiopelvimetry at much higher doses (15 to 30 mSv), found no difference in the incidence of cancer in comparison with a control group.

CONCLUSION

In conclusion, BMV in pregnancy leads to marked symptomatic relief along with no immediate detrimental effects of radiation on the fetus. Thus, BMV in pregnancy is safe, feasible and effective even in the newly emerging cardiac center like ours.

REFERENCES